The combination of a third consecutive late filing, an unfiled annual report, and the termination of the company's only revenue-generating business signals a high risk of delisting or going concern. Monitor for the actual 10-Q filing within the extension period and any subsequent auditor changes or restatements.
Price Chart
Executive Summary
Cannabis Bioscience International Holdings, Inc. (CBIH) filed a late notification (NT 10-Q) for its quarterly report for the period ended August 31, 2026, citing an inability to analyze and complete financial information on time. The company also disclosed that its Annual Report on Form 10-K for the fiscal year ended May 31, 2026, has not been filed, and it anticipates a significant decline in revenue to approximately $1,000 (from $24,200 a year ago) due to the termination of its clinical-trial business, with net loss widening to approximately $172,000 from $82,645. This is the third consecutive NT filing, indicating chronic accounting and operational problems.
Key Facts
- NT 10-Q filed for quarter ended August 31, 2026; the company's Annual Report on Form 10-K for May 31, 2026, has not been filed.
- Anticipated revenue of approximately $1,000 for the quarter, down from $24,200 in the prior-year period, due to termination of its clinical-trial business on July 31, 2026.
- Anticipated operating loss of approximately $135,000 and net loss of approximately $172,000, compared to operating loss of $74,784 and net loss of $82,645 in the prior-year quarter.
- This is the third NT filing in the past year (prior NT 10-Qs filed in January 2026 and April 2026), establishing a pattern of chronic late filings.
- The company states it cannot assure that the quarterly report will be filed within the extension period.
Financial Impact
Revenue collapse from $24,200 to ~$1,000 (down ~96%); net loss widening from $82,645 to ~$172,000 (up ~108%).
Risk Factors
- Potential SEC enforcement or delisting due to chronic late filings and unfiled annual report.
- Going concern risk as the sole revenue source (clinical-trial business) has been terminated.
- Risk of auditor resignation or change given the accounting delays and deteriorating financials.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| NT 10-Q Filing (Primary) | 0001683168-26-007933 |
| Document: 0001683168-26-007933-index-headers.html | 0001683168-26-007933 |
| Document: 0001683168-26-007933-index.html | 0001683168-26-007933 |
| Document: 0001683168-26-007933.txt | 0001683168-26-007933 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers